Pharming Group N.V. ADR (PHAR)

$14.90 +0.31 (2.09%)
Market Cap 1.02B
Revenue (ttm) 297.20M
Net Income (ttm) -11.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.98%
Debt to Equity Ratio 0.02
Volume 8,700
Avg Vol 8,424
Day's Range N/A - N/A
Shares Out 68.52M
Stochastic %K 96%
Beta 0.05
Analysts Strong Sell
Price Target $30.67

Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated pho...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 71 524 7400
Fax: 31 71 524 7445
Address:
Darwinweg 24, Leiden, Netherlands
ap20
ap20 Sep. 1 at 4:18 PM
$PHAR Happy Monday European Friends: Look like your markets are having a good day. We are closed US. ‘Hope PHAR joining in the party..
0 · Reply
Longterm007
Longterm007 Aug. 30 at 5:17 PM
$PHAR gewoon vasthouden tot KL1333 op de markt is... €10,- plus in 2030
0 · Reply
Ruconestor
Ruconestor Aug. 30 at 10:33 AM
$PHAR Ach ach de IEX bashers pushers en speculanten hebben alweer hoogtevrees dit weekend.If you cant stand the heat stay out of the Kitchen😂
1 · Reply
Ruconestor
Ruconestor Aug. 28 at 11:36 AM
$PHAR “Pharming Group’s share price reflects strong investor confidence in Ruconest and Joenja — and rightly so. The outlook is extremely bullish.”
0 · Reply
Jonita
Jonita Aug. 27 at 3:15 PM
$PHAR 💪💪💪
0 · Reply
ap20
ap20 Aug. 22 at 12:04 PM
$PHAR European PHAR’sters rolling today! Keep it up..
0 · Reply
Dutchindo
Dutchindo Aug. 22 at 9:47 AM
$PHAR
1 · Reply
HeyItsSnorlax
HeyItsSnorlax Aug. 21 at 12:16 PM
$APUS 10% of the float is shorted this will go hard. Pharma plays have been going 2-3X like $PHAR $NBYB yesterday and $APM today up 120% and the top gainer.
0 · Reply
Ruconestor
Ruconestor Aug. 21 at 7:36 AM
$PHAR Price target increased by 7.2% to €2.04 Up from €1.90, the current price target is an average from 4 analysts. New target price is 93% above last closing price of €1.05. Stock is up 44% over the past year. The company is forecast to post a net loss per share of US$0.023 next year compared to a net loss per share of US$0.018 last year. Amsterdam up nearly 4% Very strong buy
0 · Reply
Ruconestor
Ruconestor Aug. 20 at 3:01 PM
$PHAR First Berlin stockprice target Pharming on Amsterdam stock Exchange : eur 2,40 Strong buy
0 · Reply
Latest News on PHAR
Pharming Group to participate in August investor conference

Aug 4, 2025, 2:00 AM EDT - 4 weeks ago

Pharming Group to participate in August investor conference

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 3:04 PM EDT - 4 weeks ago

Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Jul 31, 2025, 1:00 AM EDT - 4 weeks ago

Pharming Group reports second quarter and first half 2025 financial results and provides business update

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Jul 17, 2025, 2:00 AM EDT - 6 weeks ago

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Jun 24, 2025, 1:00 AM EDT - 2 months ago

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Jun 11, 2025, 11:15 AM EDT - 2 months ago

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

Pharming Group to participate in June investor conferences

May 28, 2025, 2:00 AM EDT - 3 months ago

Pharming Group to participate in June investor conferences

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025, 8:50 AM EDT - 4 months ago

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

Pharming Group reports first quarter 2025 financial results and provides business update

May 8, 2025, 1:00 AM EDT - 4 months ago

Pharming Group reports first quarter 2025 financial results and provides business update

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Apr 30, 2025, 11:45 AM EDT - 4 months ago

Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director

Pharming Group to report first quarter 2025 financial results on May 8

Apr 24, 2025, 2:00 AM EDT - 4 months ago

Pharming Group to report first quarter 2025 financial results on May 8

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Apr 23, 2025, 3:30 AM EDT - 4 months ago

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Apr 3, 2025, 1:00 AM EDT - 5 months ago

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

Pharming Group to participate in April investor conferences

Mar 28, 2025, 3:00 AM EDT - 5 months ago

Pharming Group to participate in April investor conferences

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:44 PM EDT - 6 months ago

Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Mar 13, 2025, 2:00 AM EDT - 6 months ago

Pharming Group reports fourth quarter and full year 2024 financial results and provides business update

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Mar 4, 2025, 9:15 AM EST - 6 months ago

Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Feb 7, 2025, 4:00 PM EST - 7 months ago

Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

Pharming Group to convene Extraordinary General Meeting of Shareholders

Jan 21, 2025, 12:00 PM EST - 7 months ago

Pharming Group to convene Extraordinary General Meeting of Shareholders

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Jan 21, 2025, 1:00 AM EST - 7 months ago

Pharming to nominate biopharmaceutical leader Fabrice Chouraqui as new Executive Director and Chief Executive Officer

Pharming announces public cash offer to the shareholders of Abliva AB

Dec 15, 2024, 1:45 PM EST - 9 months ago

Pharming announces public cash offer to the shareholders of Abliva AB

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Dec 11, 2024, 9:34 AM EST - 9 months ago

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug

Pharming Group to participate in November investor conference

Nov 5, 2024, 2:00 AM EST - 10 months ago

Pharming Group to participate in November investor conference

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 1:44 PM EDT - 11 months ago

Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript

Pharming Group to report third quarter 2024 financial results on October 24

Oct 10, 2024, 2:00 AM EDT - 11 months ago

Pharming Group to report third quarter 2024 financial results on October 24

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Oct 10, 2024, 1:00 AM EDT - 11 months ago

Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Sep 26, 2024, 1:00 AM EDT - 1 year ago

Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)

Pharming Group to participate in September investor conferences

Sep 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group to participate in September investor conferences

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 3:26 PM EDT - 1 year ago

Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Aug 1, 2024, 1:00 AM EDT - 1 year ago

Pharming Group reports second quarter and first half 2024 financial results and provides business update

Pharming Group to report second quarter and first half 2024 financial results on August 1

Jul 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report second quarter and first half 2024 financial results on August 1

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

May 30, 2024, 4:44 PM EDT - 1 year ago

Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

May 21, 2024, 11:30 AM EDT - 1 year ago

Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders

Pharming Group to participate in May investor conference

May 20, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to participate in May investor conference

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

May 15, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

May 12, 2024, 9:19 AM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript

Pharming Group to report first quarter 2024 financial results on May 8

Apr 24, 2024, 2:00 AM EDT - 1 year ago

Pharming Group to report first quarter 2024 financial results on May 8

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Apr 24, 2024, 1:00 AM EDT - 1 year ago

Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Apr 19, 2024, 12:43 PM EDT - 1 year ago

Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025

Pharming Group announces the placement of €100 million convertible bonds due 2029

Apr 18, 2024, 9:04 AM EDT - 1 year ago

Pharming Group announces the placement of €100 million convertible bonds due 2029

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Apr 18, 2024, 2:00 AM EDT - 1 year ago

Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Apr 8, 2024, 1:00 AM EDT - 1 year ago

Pharming announces completion of enrollment in pediatric clinical trial of leniolisib

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Apr 4, 2024, 2:30 AM EDT - 1 year ago

Pharming Group announces the 2024 Annual General Meeting of Shareholders

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Apr 4, 2024, 1:00 AM EDT - 1 year ago

Pharming Group announces the filing of its 2023 Annual Report and Form 20-F

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 1:15 PM EDT - 1 year ago

Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript

Pharming Group reports fourth quarter and full year 2023 financial results

Mar 14, 2024, 2:00 AM EDT - 1 year ago

Pharming Group reports fourth quarter and full year 2023 financial results

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Feb 29, 2024, 2:00 AM EST - 1 year ago

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Pharming Group to participate in February investor conferences

Feb 8, 2024, 2:00 AM EST - 1 year ago

Pharming Group to participate in February investor conferences

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Jan 8, 2024, 1:00 AM EST - 1 year ago

Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

Dec 13, 2023, 1:00 AM EST - 1 year ago

Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)

ap20
ap20 Sep. 1 at 4:18 PM
$PHAR Happy Monday European Friends: Look like your markets are having a good day. We are closed US. ‘Hope PHAR joining in the party..
0 · Reply
Longterm007
Longterm007 Aug. 30 at 5:17 PM
$PHAR gewoon vasthouden tot KL1333 op de markt is... €10,- plus in 2030
0 · Reply
Ruconestor
Ruconestor Aug. 30 at 10:33 AM
$PHAR Ach ach de IEX bashers pushers en speculanten hebben alweer hoogtevrees dit weekend.If you cant stand the heat stay out of the Kitchen😂
1 · Reply
Ruconestor
Ruconestor Aug. 28 at 11:36 AM
$PHAR “Pharming Group’s share price reflects strong investor confidence in Ruconest and Joenja — and rightly so. The outlook is extremely bullish.”
0 · Reply
Jonita
Jonita Aug. 27 at 3:15 PM
$PHAR 💪💪💪
0 · Reply
ap20
ap20 Aug. 22 at 12:04 PM
$PHAR European PHAR’sters rolling today! Keep it up..
0 · Reply
Dutchindo
Dutchindo Aug. 22 at 9:47 AM
$PHAR
1 · Reply
HeyItsSnorlax
HeyItsSnorlax Aug. 21 at 12:16 PM
$APUS 10% of the float is shorted this will go hard. Pharma plays have been going 2-3X like $PHAR $NBYB yesterday and $APM today up 120% and the top gainer.
0 · Reply
Ruconestor
Ruconestor Aug. 21 at 7:36 AM
$PHAR Price target increased by 7.2% to €2.04 Up from €1.90, the current price target is an average from 4 analysts. New target price is 93% above last closing price of €1.05. Stock is up 44% over the past year. The company is forecast to post a net loss per share of US$0.023 next year compared to a net loss per share of US$0.018 last year. Amsterdam up nearly 4% Very strong buy
0 · Reply
Ruconestor
Ruconestor Aug. 20 at 3:01 PM
$PHAR First Berlin stockprice target Pharming on Amsterdam stock Exchange : eur 2,40 Strong buy
0 · Reply
Ruconestor
Ruconestor Aug. 20 at 7:04 AM
$PHAR https://www.zacks.com/stock/news/2673250/wall-street-analysts-think-pharming-group-phar-could-surge-145-75-read-this-before-placing-a-bet?cid=CS-STOCKTWITS-HL-tale_of_the_tape%7Cconsensus_price_target-2673250&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2673250
0 · Reply
Ruconestor
Ruconestor Aug. 20 at 7:03 AM
$PHAR The Orphan Cure Act is approved yesterday August 19 th 2025!
0 · Reply
Ruconestor
Ruconestor Aug. 20 at 6:47 AM
$PHAR De impact van de Orphan Cures Act op Pharming 1. Belangrijk voordeel bij Amerikaanse markttoegang Als Pharming haar onderzoek uitbreidt naar meerdere zeldzame indicaties (of ook naar niet-zeldzame doeleinden in de VS), biedt de . 2. Verhoging van investeringsrendement en onderzoeksincentieven • Pharming wordt gestimuleerd om vervolgindicatietrajecten te onderzoeken – ook voor aanvullende ziekten of bredere toepassingen – omdat het financieel aantrekkelijk blijft. Dat sluit aan bij BIO’s argument dat zonder dit wetsvoorstel vervolgonderzoek sterk vermindert . 3. Strategische planning in R&D • De wet maakt het aantrekkelijker om een pipeline met meerdere toepassingen te ontwikkelen. Pharming kan andere zeldzame ziektes opsporen waarvoor hun moleculen mogelijk effectief zijn, zonder de financiële bescherming te verliezen. • Het creëert ruimte voor expansie: zowel in zeldzame als “mainstream” indicaties met behoud van financiële en marktvoordelen
0 · Reply
Ruconestor
Ruconestor Aug. 20 at 6:46 AM
$PHAR De impact van de Orphan Cures Act op Pharming 1. Belangrijk voordeel bij Amerikaanse markttoegang Als Pharming haar onderzoek uitbreidt naar meerdere zeldzame indicaties (of ook naar niet-zeldzame doeleinden in de VS), biedt de Orphan Cures Act hen: • Verlengde bescherming: Meerdere orphan-designaties blijven beschermd tegen Medicare-onderhandelingen, wat prijsvrijheid en betere marges kan betekenen. • Meer zekerheid over inkomsten bij uitbreiding naar bredere indicaties, omdat alleen die bredere goedkeuringsdatum de onderhandelingsperiode start . 2. Verhoging van investeringsrendement en onderzoeksincentieven • Pharming wordt gestimuleerd om vervolgindicatietrajecten te onderzoeken – ook voor aanvullende ziekten of bredere toepassingen – omdat het financieel aantrekkelijk blijft. Dat sluit aan bij BIO’s argument dat zonder dit wetsvoorstel vervolgonderzoek sterk vermindert .
0 · Reply
Ruconestor
Ruconestor Aug. 19 at 8:57 AM
$PHAR De drie rand debielen op IEX hebben het zwaar haha. Meester Monitor en Fanaat zijn behoorlijk over hun pis bij 1 euro plus😎
0 · Reply
ap20
ap20 Aug. 18 at 9:11 PM
$PHAR I’ll take the trading today! For our overseas friends- I was just wondering if this traded much over there? (US ten day average is 13,400. I think over here it’s an adr- 1 for 10 ordinary shares.) It’s fun when it opens higher here- I guess it has gone up over there.. Thanks.
1 · Reply
ap20
ap20 Aug. 13 at 6:29 PM
$PHAR Sleeping Giant. Great time to load. Good luck.
0 · Reply
AKnewMann
AKnewMann Aug. 8 at 4:36 PM
$PHAR that's better... bought starter here.
1 · Reply
HaltTradeAlert
HaltTradeAlert Aug. 8 at 4:33 PM
$PHAR Halt Time: 12:29:50 Issue Symbol: PHAR Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
AKnewMann
AKnewMann Aug. 8 at 4:29 PM
$PHAR ridiculous spread
0 · Reply
HaltTradeAlert
HaltTradeAlert Aug. 8 at 4:10 PM
$PHAR Halt Time: 12:06:36 Issue Symbol: PHAR Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply
HaltTradeAlert
HaltTradeAlert Aug. 8 at 3:42 PM
$PHAR Halt Time: 11:41:12 Issue Symbol: PHAR Reason Code: LUDP Members get this halt alert with no delay and with more info: last stock price, volume, shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!
0 · Reply